首页> 外国专利> New bile acid conjugates with benzylamino substituted aromatic and heteroaromatic compounds useful for prevention and treatment of gall stones

New bile acid conjugates with benzylamino substituted aromatic and heteroaromatic compounds useful for prevention and treatment of gall stones

机译:新型胆汁酸与苄氨基取代的芳族和杂芳族化合物的缀合物,可用于预防和治疗胆结石

摘要

Conjugates of bile acids with benzylamino-substituted monocyclic and bicyclic aromatic and heteroaromatic compounds are new. The conjugates are compounds of formula (I) and their salts, solvates and physiologically functional derivatives (including esters and prodrugs): P'-L-G (I) G = group of formula (a): K' = OR7, NR7R8, NH-(CH2)2-CO2H, NH-(CH2)2-SO3H, NH-CH2-CO2H, N(CH3)-CH2-CO2H, NH-CH(R9)-CO2H; or OKa; Ka = cation; R7 and R8 = H, alkyl, Ph, or Ph-CH2; Ph = phenyl optionally substituted with 5 groups; R9 = alkyl, benzyl, CH2OH, (CH2)2-SCH3, CH2CO2H, or (CH2)2-CO2H; R1-R6 = H, OR10, SR10, NR10R13, OCOR10; SCOR10, NHCOR10, SO2OR10, R10, or a bond to L (one of R1-R6 is a bond to L); R10 and R13 = H, alkyl, Ph, or Ph-CH2; L = alkyl with CH2 group(s) optionally replaced by -CH=CH-, -CC-, -NR11-, -CO-, -O-, -SO2- and/or -S-; R11 = H, alkyl, COR12, phenyl, or benzyl; R12 = H, alkyl, Ph, or Ph-CH2; P' = group of formula (B1) or (B2); A, B', D' and E = N or CH; R16-R24 = H, F, Cl, Br, I, alkyl, fluoro-alkyl, CN, NO2, NR25R26, OR25, OCOR25, COR25, COOR25, CONR25R26, SO2R25, SO2OR25, or SO2NR25R26, or a bond to L (one of R16-R24 is a bond to L); and R25 and R26 = H, alkyl, fluoro-alkyl, phenyl, or benzyl. Independent claims are also included for: (A) the preparation of compounds (I); and (B) medicaments containing compounds (I) and optionally a lipid-lowering agent.
机译:胆汁酸与苄基氨基取代的单环和双环芳族和杂芳族化合物的缀合物是新的。缀合物为式(I)的化合物及其盐,溶剂化物和生理功能衍生物(包括酯和前药):P'-LG(I)G =式(a)的基团:K'= OR7,NR7R8,NH- (CH2)2-CO2H,NH-(CH2)2-SO3H,NH-CH2-CO2H,N(CH3)-CH2-CO2H,NH-CH(R9)-CO2H;或OKa; Ka =阳离子; R7和R8 = H,烷基,Ph或Ph-CH2; Ph =苯基,可选地被5个基团取代; R9 =烷基,苄基,CH2OH,(CH2)2-SCH3,CH2CO2H或(CH2)2-CO2H; R1-R6 = H,OR10,SR10,NR10R13,OCOR10; SCOR10,NHCOR10,SO2OR10,R10或与L的键(R1-R6之一为与L的键); R10和R13 = H,烷基,Ph或Ph-CH2; L =具有CH 2基团的烷基,可选地被-CH = CH-,-CC-,-NR 11-,-CO-,-O-,-SO 2-和/或-S-取代; R11 = H,烷基,COR12,苯基或苄基; R12 = H,烷基,Ph或Ph-CH2; P′=式(B1)或(B2)的基团; A,B',D'和E = N或CH; R16-R24 = H,F,Cl,Br,I,烷基,氟代烷基,CN,NO2,NR25R26,OR25,OCOR25,COR25,COOR25,CONR25R26,SO2R25,SO2OR25或SO2NR25R26或与L的键(一个R16-R24中的一个是与L的键); R 25和R 26 = H,烷基,氟代烷基,苯基或苄基。还包括以下方面的独立权利要求:(A)化合物(I)的制备; (B)含有化合物(I)和任选的降脂剂的药物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号